JAK2 and myelofibrosis: Interestingly, in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT)-1 and COMFORT-2 studies, it was observed that the benefits of ruxolitinib were independent of the presence of the JAK2 mutation [19].